Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	26.94	4.23	3.15	17.09	40.18	36.78
Short-Term Investments	259.6	291.9	219.09	211.45	-	-
Cash & Short-Term Investments	286.54	296.12	222.24	228.54	40.18	36.78
Cash Growth	-4.34%	33.24%	-2.76%	468.79%	9.23%	52.07%
Accounts Receivable	19.06	19.37	172.91	12.8	-	0.01
Other Receivables	14.28	7.17	2.42	1.61	1.09	1.42
Receivables	33.34	26.54	175.33	14.41	1.09	1.42
Prepaid Expenses	10.21	9.57	0.4	4.21	1.98	1.84
Other Current Assets	3.41	-	1.36	-	-	-
Total Current Assets	333.5	332.23	399.33	247.16	43.25	40.04
Property, Plant & Equipment	0.04	0.05	0.03	0.04	0.02	0.01
Long-Term Deferred Tax Assets	7.09	10.58	10.35	0.77	-	-
Total Assets	340.62	342.86	409.71	247.97	43.27	40.06

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.18	0.88	1.45	0.68	0.26	0.25
Accrued Expenses	-	1.53	1.45	2.74	0.72	0.56
Current Income Taxes Payable	-	-	42.87	37.12	-	-
Other Current Liabilities	-	1.94	-	2.23	0.7	-
Total Current Liabilities	7.18	4.34	45.76	42.76	1.68	0.8
Pension & Post-Retirement Benefits	0.06	0.07	0.04	-	-	-
Total Liabilities	7.24	4.41	45.8	42.76	1.68	0.8

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	133.58	134.94	165.27	173.13	167.74	167.58
Retained Earnings	215.72	210.87	180.43	38.39	-118.69	-118.88
Comprehensive Income & Other	-15.91	-7.36	18.2	-6.31	-7.46	-9.45
Shareholders' Equity	333.38	338.45	363.9	205.21	41.59	39.25
Total Liabilities & Equity	340.62	342.86	409.71	247.97	43.27	40.06

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash (Debt)	286.54	296.12	222.24	228.54	40.18	36.78
Net Cash Growth	-4.34%	33.24%	-2.76%	468.79%	9.23%	52.07%
Net Cash Per Share	2.21	2.26	1.70	1.75	0.31	0.31
Filing Date Shares Outstanding	126.77	126.64	127.01	127.27	125.97	125.97
Total Common Shares Outstanding	126.77	126.64	127.01	127.27	125.97	125.97
Working Capital	326.32	327.9	353.57	204.39	41.57	39.24
Book Value Per Share	2.63	2.67	2.87	1.61	0.33	0.31
Tangible Book Value	333.38	338.45	363.9	205.21	41.59	39.25
Tangible Book Value Per Share	2.63	2.67	2.87	1.61	0.33	0.31

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 28, 2026

Data Sources Report a data error